TODRALAZINE HYDROCHLORIDE ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H12N4O2.ClH
Molecular Weight	268.7
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TODRALAZINE HYDROCHLORIDE ANHYDROUS

Structure Search

SMILES

Cl.CCOC(=O)NNC1=C2C=CC=CC2=CN=N1

InChI

InChIKey=OMCOKCNIYWULQH-UHFFFAOYSA-N

InChI=1S/C11H12N4O2.ClH/c1-2-17-11(16)15-14-10-9-6-4-3-5-8(9)7-12-13-10;/h3-7H,2H2,1H3,(H,13,14)(H,15,16);1H

HIDE SMILES / InChI

Molecular Formula	C11H12N4O2
Molecular Weight	232.2386
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: www.drugfuture.com/mt/tocoferil-nicotinate.pdf
Curator's Comment: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/pubmed/6425526 http://www.naoru.com/Apiracohl.html http://www.ncbi.nlm.nih.gov/pubmed/9412993

Todralazine is a hydralazinophthalazine-derived drug currently used in the treatment of arterial hypertension. As vasodilator, it might be used in combination with isosorbide dinitrate. Side effects and drug toxicity were uncommon in such vasodilator therapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Collagenase 5 Target ID: CHEMBL2095216 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2169725	Activator 1447
histone acetylation 5 Target ID: GO:0016573 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17156885	Inhibitor 8504
Lysosomal alpha-glucosidase 9 Target ID: CHEMBL2608 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3266791	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: http://www.jp-orangebook.gr.jp/cgi-bin/search_h/search_e.cgi?action=detail_frame&effect=214%20&find=Todralazine%20Hydrochloride%20Hydrate	Primary		Approved 8583	Unknown Approved Use Todralazine is used as an antihypertensive agent

PubMed

Title	Date	PubMed
[The influence of guanazodine and todralazine on blood pressure regulation during dynamic and static exercise in essential hypertension (author's transl)].	1977	580022

Patents

Sample Use Guides

In Vivo Use Guide

40 – 120 mg in 3 doses per day

Route of Administration: Oral

In Vitro Use Guide

Todralazine (TDR) decreased the free radical level in granulocyte samples. At the highest of the tested TDR concentrations (80 μg/ml), the free radical level was lower by ~40% in the samples where only TDR was present than in the control samples (spontaneous release, without TDR).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:32:56 GMT 2025` Edited by `admin` on `Mon Mar 31 21:32:56 GMT 2025`
Record UNII	C59540FEXP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANHYDROUS TODRALAZINE HYDROCHLORIDE

Preferred Name

English

TODRALAZINE HYDROCHLORIDE ANHYDROUS

Common Name

English

ETHYL 3-(PHTHALAZIN-1-YL)CARBAZATE HYDROCHLORIDE

Systematic Name

English

TODRALAZINE HYDROCHLORIDE [MI]

Common Name

English

Todralazine hydrochloride [WHO-DD]

Common Name

English

ANHYDROUS TODRALAZINE HYDROCHLORIDE [MART.]

Common Name

English

Code System Code Type Description

FDA UNII

C59540FEXP